Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study

SCHIZOPHRENIA RESEARCH

卷:208

Article

Miller, Brian J.¹  Claxton, Amy²  Du, Yangchun²  Weiden, Peter J.²  Potkin, Steven G.³ 

[1] Augusta Univ, Dept Psychiat & Hlth Behav, 997 St Sebastian Way, Augusta, GA 30912 USA

[2] Alkermes Inc, Clin Dev & Med Affairs, Waltham, MA 02451 USA

[3] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA

关键词: Schizophrenia;    Antipsychotic;    Aripiprazole lauroxil;    Paliperidone palmitate;    bong-acting injection;    Switching;   

DOI  :  10.1016/j.schres.2019.01.038

来源: Elsevier

【 摘 要 】

We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP: n = 1 RLAI) enrolled: 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL. (C) 2019 The Authors. Published by Elsevier B.V.

【 授权许可】

Free